title: [Whole brain radiation with supplementary boost for patients for unique brain metastasis from a primitive lung cancer].
abstract: OBJECTIVE
  To assess the potential benefit of a boost in patients treated with whole brain irradiation by a conventional linear accelerator for lung cancer solitary brain metastasis.
  
  
  METHODS
  From 2002 to 2006, a retrospective analysis was carried out from 64 unselected consecutive patients with secondary brain metastasis from lung cancer, treated with whole brain irradiation without surgical resection. Thirty patients (47%) received a boost in their brain metastases. Three potential prognostic factors were studied: sex, RPA score and improvement of neurological symptoms after radiotherapy. An analysis was conducted to determine whether an additional dose may improve survival in the absence of surgical resection.
  
  
  RESULTS
  The mean follow-up was 4.9 months. The median overall survival was 8.5 months (6.4 to 10.7 months). The total dose of radiotherapy was the only significant prognostic factor for overall survival. The median overall survival was 6.2 months for patients without additional radiation versus 11.2 months for patients receiving a boost dose (p=0.011). Sex, RPA score and improvement of neurological symptoms after radiotherapy were not found as prognostic factors for overall survival.
  
  
  CONCLUSIONS
  Boost delivered after whole brain radiation therapy by a conventional particle accelerator may provide a benefit in selected patients, especially for centres that do not have radiotherapy techniques in stereotactic conditions. This warrants further prospective assessment.
authors.affiliation: Service de radiothérapie, groupe hospitalier Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Lévy
authors.forename: C
authors.initials: C
authors.lastname: Chargari
authors.forename: I
authors.initials: I
authors.lastname: Lamproglou
authors.forename: J-J
authors.initials: JJ
authors.lastname: Mazeron
authors.forename: C
authors.initials: C
authors.lastname: Krzisch
authors.forename: A
authors.initials: A
authors.lastname: Assouline
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000532:radiotherapy* / Q000556:secondary*; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary*; D018288:Carcinoma, Small Cell / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary*; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary; D016371:Cranial Irradiation / Q000379:methods*; D019583:Dose Fractionation, Radiation; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011882:Radiotherapy, High-Energy / Q000379:methods*; D012189:Retrospective Studies; D016896:Treatment Outcome